Tuesday May 18, 9:02 am Eastern Time
Company Press Release
Endovasc Ltd. Inc. Announces Collaboration
With Trimedyne/Cardiodyne for New Laser
Heart Treatment
MONTGOMERY, Texas--(BW HealthWire)--May 18, 1999--Endovasc Ltd. Inc. (OTC BB:ENDV - news) today
announced that the Company had entered into a collaboration with Trimedyne Inc.'s (Nasdaq:TMED - news) 90%
owned subsidiary, Cardiodyne Inc. The parties will co-develop liposomal therapeutics aimed at enhancing
Cardiodyne's revolutionary ECG synchronized Gene Injection and Laser Transmyocardial Revascularization (''TMR'')
System, which is designed to be used for treating angina, congestive heart failure, and other indications.
According to a recent Gore Horvath(a) report on Trimedyne/Cardiodyne, which estimates a multibillion dollar market,
Cardiodyne's revascularization procedure could ''potentially revolutionize the treatment of heart disease,'' especially for
the elderly, many of whom suffer from angina due to blockages in the coronary arteries and congestive heart failure.
The treatment of these conditions costs in excess of $100 billion annually in the U.S.
Dr. David P. Summers, Endovasc's chairman, said, ''Literally millions of patients with declining heart function -- most
accompanied by angina and shortness of breath, who become progressively immobilized due to the heart's inability to
push enough blood through their coronary arteries -- could be candidates for Cardiodyne's new 'cold' laser treatment
which will be combined with our liposomes containing new blood vessel growth factors. Our goal is to provide the
heart with a new blood supply network which will enable the heart to regain some of its former capabilities.''
Endovasc will collaborate with Cardiodyne on the design, development and testing of the drugs used to create new
blood vessels to and from the newly created laser channels in the heart muscle. Endovasc has liposomal products
containing Prostaglandin E-1 (Liprostin(TM)) already completed and awaiting FDA approval to commence Phase I/II
clinical trials. Endovasc recently completed design formulation for a liposome encapsulated growth factor (''VEGF''),
and will develop these and other gene encapsulation formulations during the collaboration. The Agreement gives
Cardiodyne certain rights to any products which the parties develop through the Collaboration.
About the Company:
Endovasc Ltd. Inc. is a biopharmaceutical company located in Montgomery, Texas. Endovasc uses liposomal and
nanosphere drug delivery for products that have already shown safety and efficacy in generic form. The company's
products and processes are covered by patents and trade secrets for competing in a $2 billion market.
The foregoing statements are made under the ''Safe Harbor'' Private Securities Litigation Reform Act of 1995 and may
contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this
release.
(a) Available through Gore Horvath at 800/965-8284
Contact:
PMR & Associates
Phone: 760/942-0015 or 409/448-2222
E-mail: pmrandco@aol.com
or
Endovasc Ltd. Inc.
Phone: 409/448-2222
More Quotes and News:
Endovasc Limited Inc (OTC BB:ENDV - news)
Related News Categories: biotech, medical/pharmaceutical
Help
Copyright © 1999 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of
copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of
these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing
via a computer network or in a printed form.
See our Important Disclaimers and Legal Information. |
